ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance.

18 Jun 2014

New path may lead to powerful adjunctive novel therapy for PTSD treatment

There are currently only two FDA-approved medications for the treatment of posttraumatic stress disorder (PTSD) in the United States. Both of these medications are serotonin uptake inhibitors. Despite the availability of these medications, many people diagnosed with PTSD remain symptomatic, highlighting the need for new medications for PTSD treatment.

12 Jun 2014

Researchers emphasize critical need to utilize multi-pronged approach to treat diabetes mellitus

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University; Marc A. Pfeffer, M.D., Dzau professor of medicine at Harvard Medical School; John W. Newcomer, M.D., executive vice dean of FAU's College of Medicine and interim vice president for research at FAU; Paul S. Jellinger, M.D., affiliate professor at the University of Miami Miller School of Medicine; and Alan Garber, M.D., Ph.D., professor of medicine at Baylor, have published a commentary in the American Journal of Managed Care titled "Treatment of Diabetes Mellitus: The Urgent Need for Multifactorial Interventions."

4 Jun 2014

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant.

19 May 2014

Investigators find effective treatment for life-threatening angioedema attacks in ED

Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.

15 May 2014

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

6 Mar 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

ACE protein overexpression elevates immune responses and prevents Alzheimer's-like cognitive decline

Many people with high blood pressure are familiar with ACE inhibitors, drugs that widen blood vessels by limiting activity of ACE - angiotensin-converting enzyme - a naturally occurring protein found in tissues throughout the body.

4 Feb 2014

FDA approves Actavis' ANDA for Telmisartan Immediate-Release Tablets

Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.

9 Jan 2014

New guideline to help doctors treat patients with hypertension

A new guideline developed by evidence gathered from randomized clinical trials for the management of high blood pressure contains nine recommendations and a treatment algorithm to help doctors treat patients with hypertension.

19 Dec 2013

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.

8 Nov 2013

Simple urine test can help identify disease risks in young type 1 diabetes patients

Using a simple urine test, researchers can now identify young people with type 1 diabetes at risk of heart and kidney disease. The new research, funded by JDRF, Diabetes UK, and the British Heart Foundation, was published today, 06 November, in the journal Diabetes Care.

7 Nov 2013

Heart failure patients may benefit from advanced treatment by heart specialists

New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists - something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure.

4 Nov 2013

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

A Johns Hopkins-led analysis of data previously gathered on more than 3,000 elderly Americans strongly suggests that taking certain blood pressure medications to control blood pressure may reduce the risk of dementia due to Alzheimer's disease.

17 Oct 2013

Personalised therapy can reduce risk of cardiac disease among diabetes patients

600,000 to 800,000 Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy.

8 Oct 2013

Hypertension Drug May Aid Cancer Treatment

...

2 Oct 2013

Loyola's success in implementing standard of care for heart attack patients recognized by AHA

Loyola University Medical Center has received the American Heart Association's Mission: Lifeline Silver Receiving Quality Achievement Award, which recognizes Loyola's commitment and success in implementing an exceptional standard of care for heart attack patients.

29 Aug 2013

Implementation of large-scale hypertension program linked with doubling of hypertension control rates

Implementation of a large-scale hypertension program that included evidence-based guidelines and development and sharing of performance metrics was associated with a near-doubling of hypertension control between 2001 and 2009, compared to only modest improvements in state and national control rates, according to a study in the August 21 issue of JAMA.

21 Aug 2013

Study observes that long-term use of antihypertensive drugs associated with breast cancer risk

Older women who take certain types of medication to combat high blood pressure may be putting themselves at greater risk for developing breast cancer, according to a new study by a team of Fred Hutchinson Cancer Research Center scientists led by Christopher Li, M.D., Ph.D.

6 Aug 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013